Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes
Open Access
- 2 February 2017
- journal article
- research article
- Published by Wiley in Cancer Cytopathology
- Vol. 125 (5) , 313-322
Abstract
BACKGROUND: Thyroid nodules with atypia of undetermined significance (AUS) on fine‐needle aspiration (FNA) have a low risk of malignancy that appears to vary based on specific features described in the AUS diagnosis. The Afirma gene expression classifier (GEC) is a molecular test designed to improve preoperative risk stratification of thyroid nodules, but its performance for different patterns of AUS has not been defined. The objective of this study was to assess GEC results and clinical outcomes in AUS nodules with architectural atypia (AUS‐A), cytologic atypia (AUS‐C) or both (AUS‐C/A).METHODS: This was a retrospective review of all thyroid nodules with AUS cytopathology that underwent GEC testing at the authors' institution over a period of >4 years.RESULTS: In 227 nodules that had AUS cytology results and Afirma GEC testing, the rate of benign GEC results was higher in AUS‐A nodules (70 of 107; 65%) than in AUS‐C/A nodules (25 of 65; 38%; P = .0008), and AUS‐C nodules exhibited an intermediate rate of benign results (27 of 55 nodules; 59%). The risk of cancer among patients who had GEC‐suspicious nodules, 86% of whom underwent resection, was 19% (6 of 25) for AUS‐A nodules compared with 57% (21 of 37) for AUS‐C/A nodules (P = .003) and 45% (10 of 22) for AUS‐C nodules (P = .07). In nodules that had an indeterminate repeat cytology result, no difference was observed in the rate of benign GEC results or in the malignancy rate compared with nodules that had a single cytology result.CONCLUSIONS: The performance characteristics of Afirma GEC testing vary, depending on qualifiers of cytologic atypia. Recognition of these differences may enable clinicians to provide improved counseling and treatment recommendations to patients. Cancer Cytopathol 2017;125:313–322. © 2017 American Cancer Society.Keywords
This publication has 53 references indexed in Scilit:
- Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate CytologyNew England Journal of Medicine, 2012
- Thyroid NodulesMedical Clinics of North America, 2012
- Variability in the Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Diagnosis in the Bethesda System for Reporting Thyroid Cytopathology: Sources and RecommendationsActa Cytologica, 2011
- Spectrum of Risk of Malignancy in Subcategories of ‘Atypia of Undetermined Significance’Acta Cytologica, 2011
- Eliminating the “Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance” Category From the Bethesda System for Reporting Thyroid CytopathologyAmerican Journal of Clinical Pathology, 2011
- Should “atypical follicular cells” in thyroid fine-needle aspirates be subclassified?Cancer Cytopathology, 2010
- Fine‐needle aspiration of follicular patterned lesions of the thyroid: Diagnosis, management, and follow‐up according to National Cancer Institute (NCI) recommendationsDiagnostic Cytopathology, 2010
- Molecular Testing for Mutations in Improving the Fine-Needle Aspiration Diagnosis of Thyroid NodulesThe Journal of Clinical Endocrinology & Metabolism, 2009
- Follicular-Patterned Lesions of the ThyroidAmerican Journal of Clinical Pathology, 2002
- Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996Cancer, 2000